Evidence map›Paper›PMID 25749523›Full record

ArticleOncotarget2015

Treatment-induced cell cycle kinetics dictate tumor response to chemotherapy.

Robin M Hallett, Cheng Huang, Ali Motazedian, Stefanie Auf der Mauer, Gregory R Pond, John A Hassell, Robert E Nordon, Jonathan S Draper

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Robin M HallettDepartment of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON L8N 3Z5, Canada.
Cheng HuangMcMaster Stem Cell and Cancer Research Institute, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON L8N 3Z5, Canada.
Ali MotazedianMcMaster Stem Cell and Cancer Research Institute, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON L8N 3Z5, Canada.
Stefanie Auf der MauerGraduate School of Biomedical Engineering, University of New South Wales, Sydney 2052, Australia.
Gregory R PondDepartment of Oncology, McMaster University, Hamilton, ON L8N 3Z5, Canada.
John A HassellDepartment of Pathology and Molecular Medicine, McMaster University, Hamilton, ON L8N 3Z5, Canada.
Robert E NordonGraduate School of Biomedical Engineering, University of New South Wales, Sydney 2052, Australia.
Jonathan S DraperMcMaster Stem Cell and Cancer Research Institute, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON L8N 3Z5, Canada.
McMaster University · CAUNSW Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chemotherapy fails to provide durable cure for the majority of cancer patients. To identify mechanisms associated with chemotherapy resistance, we identified genes differentially expressed before and after chemotherapeutic treatment of breast cancer patients. Treatment response resulted in either increased or decreased cell cycle gene expression. Tumors in which cell cycle gene expression was increased by chemotherapy were likely to be chemotherapy sensitive, whereas tumors in which cell cycle gene transcripts were decreased by chemotherapy were resistant to these agents. A gene expression signature that predicted these changes proved to be a robust and novel index that predicted the response of patients with breast, ovarian, and colon tumors to chemotherapy. Investigations in tumor cell lines supported these findings, and linked treatment induced cell cycle changes with p53 signaling and G1/G0 arrest. Hence, chemotherapy resistance, which can be predicted based on dynamics in cell cycle gene expression, is associated with TP53 integrity.

Indexed as

Antineoplastic AgentsBreast NeoplasmsCell CycleCell Line, TumorDrug Resistance, NeoplasmFemaleFlow CytometryGene Expression ProfilingGene Expression Regulation, NeoplasticGenes, ReporterHumansImmunohistochemistryMCF-7 CellsNeoplasmsSignal TransductionTumor Suppressor Protein p53Antineoplastic AgentsTP53 protein, humanTumor Suppressor Protein p53breast cancercell cyclechemotherapyp53

Identifiers

PMID25749523
PMCPMC4466668
OpenAlexW1556571873

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.